Free Trial
→ Alert: Prepare for Trump's Dollar Overhaul (From Brownstone Research) (Ad)tc pixel

CytoDyn (OTCMKTS:CYDY) Shares Up 17.5% - What's Next?

Written by MarketBeat
September 10, 2025
CytoDyn logo with Medical background

Key Points

  • CytoDyn Inc. shares increased by 17.5% on Monday, reaching a high of $0.38 and closing at $0.37, with a trading volume of 5,638,735 shares, significantly above the average.
  • The company reported a market capitalization of $467.26 million and a PE ratio of 37.22 as of the last trading session.
  • CytoDyn is involved in the clinical development of leronlimab, a monoclonal antibody targeting conditions such as COVID-19, HIV, and various cancers.
  • Five stocks we like better than CytoDyn.

Shares of CytoDyn Inc. (OTCMKTS:CYDY - Get Free Report) shot up 17.5% on Monday . The company traded as high as $0.38 and last traded at $0.37. 5,638,735 shares were traded during trading, an increase of 221% from the average session volume of 1,757,202 shares. The stock had previously closed at $0.32.

CytoDyn Trading Up 17.5%

The business has a fifty day simple moving average of $0.29 and a two-hundred day simple moving average of $0.29. The stock has a market cap of $467.26 million, a PE ratio of 37.22 and a beta of 1.42.

CytoDyn (OTCMKTS:CYDY - Get Free Report) last posted its earnings results on Friday, July 25th. The biotechnology company reported ($0.01) earnings per share for the quarter.

About CytoDyn

(Get Free Report)

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in CytoDyn Right Now?

Before you consider CytoDyn, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CytoDyn wasn't on the list.

While CytoDyn currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.